Journal article
Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity
Carina CD Joe, Sayantani Chatterjee, George Lovrecz, Timothy E Adams, Morten Thaysen-Andersen, Renae Walsh, Stephen A Locarnini, Peter Smooker, Hans J Netter
Vaccine | ELSEVIER SCI LTD | Published : 2020
Abstract
Virus-like particles (VLP) represent biological platforms for the development of novel products such as vaccines and delivery platforms for foreign antigenic sequences. VLPs composed of the small surface antigen (HBsAgS) derived from the hepatitis B virus (HBV) are the immunogenic components of a licensed, preventative vaccine, which contains aluminum hydroxide as adjuvant. Herein, we report that glycoengineering of N-glycosylated HBsAgS to generate hyper-glycosylated VLPs display an enhanced immunogenicity relative to the wild type (WT) HBsAgS VLPs when expressed in FreeStyle HEK 293F cells. Comparative mass spectrometry-based N-glycan profiling, gel electrophoresis, and immunoassays demons..
View full abstractGrants
Awarded by National Health and Medical Research Council Australia
Awarded by International Macquarie University Research Excellence Scholarship
Funding Acknowledgements
C.J. was supported by a postgraduate scholarship awarded by RMIT University and CSIRO. H.J.N. and S.A.L. were partially supported by the National Health and Medical Research Council Australia (research grant APP1127538). H.J.N. was also supported by a grant awarded by the Australian Centre for HIV and Viral Hepatitis Research (ACH2). M.T.-A. was supported by a Macquarie University Research Seeding Grant (MQRSG). S.C. was supported by an International Macquarie University Research Excellence Scholarship (iMQRES 2017152). Ms Rachel Hammond, VIDRL, is acknowledged for her excellent technical support.